Exchange: AMEX Industry: Biotechnology
-3.77% $1.530
America/New_York / 10 mai 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 12.08 mill |
EPS: | -49.92 |
P/E: | -0.0300 |
Earnings Date: | May 15, 2024 |
SharesOutstanding: | 7.90 mill |
Avg Daily Volume: | 1.519 mill |
RATING 2024-05-10 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0300 | sector: PE 12.30 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -0.0300 | industry: PE -5.55 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.186 - 1.874 ( +/- 22.48%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-06 | Otto Daniel A | Sell | 0 | Common Stock |
2024-04-06 | Staffeldt Jonathan | Sell | 0 | Common Stock |
2024-01-05 | Arno Andrew | Buy | 100 000 | Common Stock |
2024-01-04 | Firestone Lawrence | Buy | 100 000 | Common Stock |
2023-12-01 | Firestone Lawrence | Buy | 0 |
INSIDER POWER |
---|
67.14 |
Last 91 transactions |
Buy: 8 846 121 | Sell: 4 190 953 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.530 (-3.77% ) |
Volume | 0.157 mill |
Avg. Vol. | 1.519 mill |
% of Avg. Vol | 10.33 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.